Drug Profile
NSI 566
Alternative Names: hCNS-SC - Palisade Bio; HuCNS-SC - Palisade Bio; Neural Stem Cells - Palisade Bio; NSI-566; NSI-566RSCLatest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator Neuralstem
- Developer Emory University; HK inno.N; Neuralstem China; Palisade Bio; Seneca Biopharma; University of California, San Diego; University of Freiburg
- Class Neural stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements; Neurogenesis stimulants; Neuron stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II/III Paralysis
- Phase II Amyotrophic lateral sclerosis
- No development reported Spinal cord injuries
- Discontinued Alzheimer's disease; Brain injuries; Cerebral palsy; Cognition disorders; Diabetic neuropathies; Huntington's disease; Lysosomal storage diseases; Multiple sclerosis; Optic neuritis; Paraplegia; Parkinson's disease
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for phase-I development in Spinal-cord-injuries in USA (Intraspinal, Injection)
- 27 Apr 2021 Leading BioSciences has merged with Seneca Biopharma to form Palisade Bio
- 27 Apr 2021 Leading BioSciences has merged with Seneca Biopharma to form Palisade Bio